AzTrials
AzTrials

Pulmonary Embolism (Diagnosis)NCT07412418

Screening for Pulmonary Embolism Using Single-channel Electrocardiogram

An observational study of Pulmonary Embolism (Diagnosis) and Respiratory Failure With Hypoxia, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
How many people
500 participants
Where
1 siteRussia
Study dates
1 May 2026to 30 Jul 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample. The study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental). During the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines

Who may be able to join

  • A clinical condition requiring exclusion of acute pulmonary embolism;
  • The presence of written informed consent of the patient to participate in the study;
  • Age from 18 years old and older
  • Non-inclusion criteria:
  • Refusal to undergo examination or the inability to reliably verify or exclude the diagnosis of pulmonary embolism;
  • Treatment, in particular anticoagulant therapy, before recording a single-lead ECG;
  • Conditions in which recording an ECG in lead I is not possible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs, tremor, etc.);
  • Refusal to sign written informed consent to participate in the study.

Who cannot join

  • Poor ECG quality, preventing the necessary analysis of a single-channel ECG;
  • Incomplete examination, preventing a reliable determination of the presence or absence of pulmonary embolism;
  • Refusal to further participate in the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Petr Chomakhidze, Professor contact

+79166740369

chomakhidze_p_sh@staff.sechenov.ru

Aliya Khusyainova, Dr. contact

+79832824402

khusyainova1997@bk.ru

Russia1 site
  • University Clinical Hospital №1, Sechenov University

    Moscow

Other trials in Russia

About this study

Official title: Screening for Pulmonary Embolism Using Single-channel Electrocardiogram Data Using Machine Learning Models

It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample.

The study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental).

Read more

During the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines.

All patients included in the study will undergo electrocardiogramm (ECG) in standart lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the Remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transformation. The result of this study will be the identification of ECG parameters that will correlate with pulmonary embolism.

Read the detailed description

The aim of the study: to create and evaluate the diagnostic efficiency of an algorithm for detecting pulmonary embolism using digital analysis of a single-channel ECG using elements of artificial intelligence. It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample). The study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental). During the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines.

All patients included in the study will undergo ECG recording in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. Single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Supervision on February 15, 2019. RZN No. 2019/8124.

The patient's personal data (last name, first name, patronymic, date of birth, contact information) will not be transferred or taken into account. Each patient is assigned an individual number that is not associated with his/her personal data. Then a spectral analysis of the electrocardiogram will be performed using a continuous wavelet transformation, the principles of which are based on the Fourier transform method. The analysis involves the evaluation of the following parameters (the parameters listed below will be calculated as the median of the tact-cycle):• TpTe - time from peak to end of the T-wave• VAT - time from the beginning of the QRS to the R-peak• QTc - corrected QT interval.• QT / TQ - the ratio of QT length to TQ length (from the end of T to the beginning of the QRS of the next complex).• QRS_E - the total energy of the QRS wave based on the wavelet transform• T_E - T-wave total energy based on wavelet transform• TP_E- energy of the main tooth of the T-wave based on the wavelet transform• BETA, BETA_S - T-wave asymmetry coefficients (simple and smooth versions)• BAD_T - flag of T-wave quality (whether expressed in the current lead• QRS_D1_ons - energy of the leading edge of the R-wave (based on the "first derivative" wavelet transform)• QRS_D1_offs - energy of the trailing edge of the R-wave (based on the "first derivative" wavelet transform)• QRS_D2 - peak energy of the R-wave (based on the "second derivative" wavelet transform)• QRS_Ei (i = 1,2,3,4) - QRS-wave energy in 4 frequency ranges (2-4-8-16-32 Hz) based on wavelet transform• T_Ei (i = 1,2,3,4) - T-wave energy in 4 frequency ranges (2-4-6-8-10 Hz) based on wavelet transform• HFQRS - the amplitude of the RF components of the QRS wave. Additionally used parameters:• TpTe, VAT, QTc - are duplicated to control the correctness of the record processing (the value of the UCC should be approximately equal to the median of the tick-by-bar).• QRSw - QRS width.• RA, SA, TA - the amplitudes of the R, S, T-waves, respectively, are used to normalize the parameters listed above.

Statistical analysis and modeling will be performed using Python V3.8.8 and R V.4.0, as well as SPSS v.17. The correlation between various combinations of ECG time, amplitude, energy, and frequency parameters and the presence or absence of PE will be analyzed. Specific parameters will be incorporated into various multivariate analysis and machine learning models: Lasso regression, random forest, multilayer perceptron, support vector machine, and decision tree. The model with the highest diagnostic accuracy will be selected and used to test the algorithm.

The outcome of this study will be the development and testing of an algorithm for pulmonary embolism detection using digital analysis of a single-channel ECG witj elements of artificial intelligence.

The endpoints of the study are the parameters of diagnostic accuracy of the developed model:

  • specificity,
  • sensitivity,
  • prognostic significance of a positive and negative result,
  • diagnostic accuracy. Тhese metrics will be calculated using receiver operating characteristic (ROC) analysis and confusion matrices on a held-out test set (30% of the dataset) after training multifactorial models (logistic regression, random forest, or neural networks) on single-lead ECG features. Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of pulmonary embolism against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.
Keywords
Screening, single-channel electrocardiogram, machine learning models, pulmonary embolism, respiratory failure, chronic obstructive pulmonary disease
Medical subject headings
Pulmonary Embolism, Disease, Pulmonary Disease, Chronic Obstructive, Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07412418
Study groupRoleWhat they receive
Training sample300 patients 18 years old and older with and without pulmonary embolism confirmed by the results of full examination (laboratory, clinical and instrumental) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA and others).
Test sample200 patients 18 years old and older with and without pulmonary embolism confirmed by the results of full examination (laboratory, clinical and instrumental) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA and others).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determination of sensitivity of pulmonary embolism of multivariate models for analyzing single-channel electrocardiogram data

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Measured: through study completion, an average of 2 years

  2. Parameters of single-channel ECG that significantly correlate with the presence of pulmonary embolism;

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Measured: through study completion, an average of 2 years

  3. Determination of specificity of pulmonary embolism of multivariate models for analyzing single-channel electrocardiogram data

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Measured: through study completion, an average of 2 years

  4. Determination of diagnostic accuracy of pulmonary embolism of multivariate models for analyzing single-channel electrocardiogram data

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Measured: through study completion, an average of 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2026
  2. Study start1 May 2026 (estimated)
  3. Primary completion30 Mar 2028 (estimated)
  4. Study completion30 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07412418
Sponsor's protocol ID
ChPSH2226
Status last verified
Feb 2026
First submitted
9 Feb 2026
Last updated
1 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: It is not possible to provide documentation due to the prohibition received from the local ethics committee

Questions about this trial

What is this clinical trial studying?

An observational study of Pulmonary Embolism (Diagnosis) and Respiratory Failure With Hypoxia, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Petr Chomakhidze, Professor (+79166740369, chomakhidze_p_sh@staff.sechenov.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determination of sensitivity of pulmonary embolism of multivariate models for analyzing single-channel electrocardiogram data (time frame: through study completion, an average of 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in